EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer

Jinyuan Gu, Jiaming Wang, Yue Sun, Xinrui Mao, Chao Qian, Xinyu Tang, Ji Wang, Hui Xie, Lijun Ling, Yi Zhao iD, Xiaoan Liu, Kai Zhang iD und 4 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jinyuan Gu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Tumor Microenvironment, Tertiary Lymphoid Structures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Locoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.

Methods

We retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.

Results

We found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup ( p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup ( p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor ( p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors ( p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors ( p = 0.037).

Conclusion

Our study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalTumor MicroenvironmentTertiary Lymphoid StructuresProgression-Free SurvivalHumansFemaleMiddle AgedRetrospective StudiesPrognosisAdultAgedAntigens, CDReceptors, EstrogenAntigens, Differentiation, MyelomonocyticLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

immune cellslocoregional recurrent breast cancerprognostic predictorprogression‐free survivaltertiary lymphoid structures

Substanzen

Antigens, CDReceptors, EstrogenAntigens, Differentiation, Myelomonocytic

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Department of General Surgery, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
  • Pancreas Center & Department of General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
  • Pancreas Institute of Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Yi Zhao, Kai Zhang, Shui Wang, Cong Wang, Wenbin Zhou

Förderung

  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • National Natural Science Foundation of China

Zitieren

APA

Gu, J., Wang, J., Sun, Y., Mao, X., Qian, C., Tang, X., Wang, J., Xie, H., Ling, L., Zhao, Y., Liu, X., Zhang, K., Pan, H., Wang, S., Wang, C., & Zhou, W. (2024). Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6864

Vancouver

Gu J, Wang J, Sun Y, Mao X, Qian C, Tang X, et al. Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer. Cancer Medicine. 2024. doi:10.1002/cam4.6864

BibTeX
@article{Gu2024,
  author = {Gu, Jinyuan and Wang, Jiaming and Sun, Yue and Mao, Xinrui and Qian, Chao and Tang, Xinyu and Wang, Ji and Xie, Hui and Ling, Lijun and Zhao, Yi and Liu, Xiaoan and Zhang, Kai and Pan, Hong and Wang, Shui and Wang, Cong and Zhou, Wenbin},
  title = {Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6864}
}
Kostenlos starten →